DHODH and cancer: promising prospects to be explored

Table 3 Molecular structures and IC₅₀ values for recently developed novel DHODH inhibitors

Compound	Disease	Activity/IC₅₀	Reference
C07	AML	1.3 μM	[107]
DD264	Measles virus	15 μM	[107, 128]
DSM265	Malaria	41 μg/mL	[123]
DSM430	Malaria	3.7 μg/mL	[123]
DSM450	Malaria	Higher than 43 μg/mL	[123]
GSK983	Chronic myelogenous leukemia K562 cells	21 nM	[159]
HZ-05	Melanoma	32 ± 2 nM	[35, 61]
IBC	AML Hl60 cells	0.36 ± 0.05 μM	[70]
ML390	AML	0.56 μM	[107]
IMU-838	Ulcerative colitis, multiple sclerosis	/	[153, 160]
OSU-03012	/	/	[112, 130]
PP-001	Inflammation and chorioretinal neovascularization	Lower than 4 nM	[107, 161]
P1788	/	EC₅₀ 44 μM	[158]
TAK-632	/	/	[112, 130]
Vidofludimus (4SC-101)	Colitis, systemic lupus erythematosus	0.134 ± 0.016 μM	[153]
Compound 1	/	6 nM	[162]
Compound 2	/	773 μM	[162]
Compound 3	Rheumatoid arthritis	280 nM	[18]
Compound 4	Rheumatoid arthritis	2 nM	[18]
Compound 5	/	K_i 2.8 μM	[163]
Compound 6	/	15 nM	[102]
Compound 7	/	81 nM	[102]
Compound 8	/	69 nM	[102]
Compound 11l	AML CRC Melanoma	4.5 nM	[164]
Compound 11k	AML CRC Melanoma	9.0 nM	[164]

ISSN: 2049-3002